Orchid Pharma has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) based on the successful inspection closure for the Post-marketing Adverse Drug Experience reporting inspection (PADE) conducted at Orchid Towers 313, Valluvar Kottam High Road, Nungambakkam, Chennai, Tamil Nadu, India. The facility was inspected by USFDA in the month of June 2017.
Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.
